Literature DB >> 22658745

Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome.

Aarti Ruparelia1, Matthew L Pearn, William C Mobley.   

Abstract

Down syndrome (DS) is a multi-faceted condition resulting in the most common genetic form of intellectual disability. Mouse models of DS, especially the Ts65Dn model, have been pivotal in furthering our understanding of the genetic, molecular and neurobiological mechanisms that underlie learning and memory impairments in DS. Cognitive and pharmacological insights from the Ts65Dn mouse model have led to remarkable translational progress in the development of therapeutic targets and in the emergence of DS clinical trials. Unravelling the pathogenic role of trisomic genes on human chromosome 21 and the genotype-phenotype relationship still remains a pertinent goal for tackling cognitive deficits in DS.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22658745      PMCID: PMC3434300          DOI: 10.1016/j.conb.2012.05.002

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  59 in total

1.  NMDA-mediated regulation of DSCAM dendritic local translation is lost in a mouse model of Down's syndrome.

Authors:  Alexandra Alves-Sampaio; José Antonio Troca-Marín; María Luz Montesinos
Journal:  J Neurosci       Date:  2010-10-06       Impact factor: 6.167

Review 2.  Trisomy 21 and early brain development.

Authors:  Tarik F Haydar; Roger H Reeves
Journal:  Trends Neurosci       Date:  2011-12-09       Impact factor: 13.837

Review 3.  Dementia and mortality in persons with Down's syndrome.

Authors:  A Coppus; H Evenhuis; G-J Verberne; F Visser; P van Gool; P Eikelenboom; C van Duijin
Journal:  J Intellect Disabil Res       Date:  2006-10

4.  Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome.

Authors:  Patrizia Bianchi; Elisabetta Ciani; Sandra Guidi; Stefania Trazzi; Daniela Felice; Gabriele Grossi; Mercedes Fernandez; Alessandro Giuliani; Laura Calzà; Renata Bartesaghi
Journal:  J Neurosci       Date:  2010-06-30       Impact factor: 6.167

5.  Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.

Authors:  X Altafaj; M Dierssen; C Baamonde; E Martí; J Visa; J Guimerà; M Oset; J R González; J Flórez; C Fillat; X Estivill
Journal:  Hum Mol Genet       Date:  2001-09-01       Impact factor: 6.150

6.  Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome.

Authors:  Noemí Rueda; María Llorens-Martín; Jesús Flórez; Elsa Valdizán; Pradeep Banerjee; Jose Luis Trejo; Carmen Martínez-Cué
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

7.  The four ages of Down syndrome.

Authors:  Alan H Bittles; Carol Bower; Rafat Hussain; Emma J Glasson
Journal:  Eur J Public Health       Date:  2006-07-19       Impact factor: 3.367

Review 8.  Cognitive deficits and associated neurological complications in individuals with Down's syndrome.

Authors:  Ira T Lott; Mara Dierssen
Journal:  Lancet Neurol       Date:  2010-06       Impact factor: 44.182

9.  Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.

Authors:  William J Netzer; Craig Powell; Yi Nong; Jacqueline Blundell; Lili Wong; Karen Duff; Marc Flajolet; Paul Greengard
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

10.  Prevention of developmental delays in a Down syndrome mouse model.

Authors:  Laura Toso; Irene Cameroni; Robin Roberson; Daniel Abebe; Stephanie Bissell; Catherine Y Spong
Journal:  Obstet Gynecol       Date:  2008-12       Impact factor: 7.623

View more
  9 in total

1.  Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model.

Authors:  Ishita Das; Joo-Min Park; Jung H Shin; Soo Kyeong Jeon; Hernan Lorenzi; David J Linden; Paul F Worley; Roger H Reeves
Journal:  Sci Transl Med       Date:  2013-09-04       Impact factor: 17.956

2.  Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease.

Authors:  Barbara J Strupp; Brian E Powers; Ramon Velazquez; Jessica A Ash; Christy M Kelley; Melissa J Alldred; Myla Strawderman; Marie A Caudill; Elliott J Mufson; Stephen D Ginsberg
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

3.  Proteomic analysis of six- and twelve-month hippocampus and cerebellum in a murine Down syndrome model.

Authors:  Guido N Vacano; David S Gibson; Abdullah Arif Turjoman; Jeremy W Gawryluk; Jonathan D Geiger; Mark Duncan; David Patterson
Journal:  Neurobiol Aging       Date:  2017-11-26       Impact factor: 4.673

4.  Detoxification Improves Multidomain Cognitive Dysfunction in High-Dose Benzodiazepine Abusers.

Authors:  Angela Federico; Fabio Lugoboni; Elisa Mantovani; Alice Martini; Laura Morbioli; Rebecca Casari; Marco Faccini; Stefano Tamburin
Journal:  Front Neurosci       Date:  2020-07-21       Impact factor: 4.677

5.  A 'cure' for Down syndrome: what do parents want?

Authors:  A Inglis; Z Lohn; J C Austin; C Hippman
Journal:  Clin Genet       Date:  2014-03-21       Impact factor: 4.438

Review 6.  Disinhibition, an emerging pharmacology of learning and memory.

Authors:  Hanns Möhler; Uwe Rudolph
Journal:  F1000Res       Date:  2017-02-03

Review 7.  Enhanced GIRK2 channel signaling in Down syndrome: A feasible role in the development of abnormal nascent neural circuits.

Authors:  Alexander M Kleschevnikov
Journal:  Front Genet       Date:  2022-09-12       Impact factor: 4.772

8.  Synaptic Vesicle Recycling Is Unaffected in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Jamie R K Marland; Karen J Smillie; Michael A Cousin
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

9.  Long-lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5-selective GABAA inverse agonist.

Authors:  Arnaud Duchon; Agnès Gruart; Christelle Albac; Benoît Delatour; Javier Zorrilla de San Martin; José María Delgado-García; Yann Hérault; Marie-Claude Potier
Journal:  Br J Pharmacol       Date:  2020-01-09       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.